Firmagon FDA Approval History
FDA Approved: Yes (First approved December 24, 2008)
Brand name: Firmagon
Generic name: degarelix
Dosage form: for Injection
Company: Ferring Pharmaceuticals, USA
Treatment for: Prostate Cancer
Firmagon (degarelix) is an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer.
Development Timeline for Firmagon
|Dec 29, 2008||FDA Approves Ferring Pharmaceuticals' Degarelix for Treatment of Advanced Prostate Cancer|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.